Redafamdastat
Redafamdastat is an inhibitor of the enzyme fatty acid amide hydrolase, with an of 7.2nM, and both analgesic and anti-inflammatory effects in animal studies comparable to those of the cyclooxygenase inhibitor naproxen. It was being developed by Jazz Pharmaceuticals for the treatment of alcoholism, pain, and post-traumatic stress disorder and reached phase 2 clinical trials. However, development of the drug was discontinued in December 2023.